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Personal perspective

Halfway there:
the struggle to manage conflicts of interest
Arthur L. Caplan
Department of Medical Ethics and Center for Bioethics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Conflicts of interest are known to create problems for the integrity of biomedical research. The editors of the JCI
have set out a rigorous policy to help manage conflicts. But they focus only on financially generated conflicts. Here
I identify other sources of conflict and offer some suggestions for their management.
Could there be any more treacherous terrain for an editorial
board to enter these days than conflict of interest? The mere
mention of the subject suffices to elicit from scientists and
researchers groans, rolled eyes, pursed lips, and not a few imprecations — the cataloguing of which, while eye-opening, will never
appear in the pages of this or any other prestigious biomedical
journal. Yet the new editors have chosen to set out a conflictof-interest policy regarding financial conflicts that goes further
than any other I am familiar with.
Not only have the new editors set out guidelines for authors, but
they have imposed standards upon themselves and upon reviewers
as well (1). While one can quibble about the dollar amounts that
trigger concern, the fact that the new policy not only enters into
the terrain of financial conflict but pioneers new frontiers in terms
of scope and precision is nothing but commendable. That said,
the policy set out in this issue will not prove adequate. No policy
focused solely on financial conflict could.
Money is an important source of conflict: study after study has
shown the power that money can have in the publication of scientific findings (2–6). The new JCI policy rightly attempts to limit the
pull that a financial stake can create in decisions to publish a manuscript, interpret data in a positive light, or omit data and interpretations that are less than flattering to personal bottom lines.
The problem is that there are more sources of conflict of interest than money, and these conflicts are mentioned only briefly
in the second tier of the new JCI policy. Some of the most notorious scandals in the biomedical sciences in recent years have been
fueled as much by the desire for fame or to be first as by financial return. The greatest fraud in the recent history of science
— the claim to have created viable stem cell lines from cloned
human embryos — was influenced by many factors, but money
was not among them (7).
Not only does ambition create conflict, but so do politics, personal rivalries, the lust for power, institutional pressures, the drive
to secure tenure, the desire for prizes and awards, and even the
desire simply to please one’s peers. The new policy is silent about
these types of conflicts of interest, but they most certainly exist.
So what are the editors of the JCI to do? Return to the current policy at a later date and amend it? Ought they require that
in addition to financial disclosures, all editors, contributors,
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and reviewers submit biographies and psychological profiles on
themselves to be published in tiny agate type? Should the editors,
in the name of rooting out nonfinancial conflicts of interest,
publish all possible facts about authors’, reviewers’, and editors’
tastes, religious views, political affiliations, sexual orientation,
churchgoing habits, intrafamilial rivalries, and graduate school
grudges? Soon the JCI would consist of little but endless, difficult-to-read autobiographies!
The answer to the question of how to deal with all forms of conflict
of interest is not disclosure or transparency; rather, it requires integrity.
But even integrity is not sufficient. Since the days when journals first
appeared, editors realized that something else was required.
The antidote to fame, power, politics, and greed seized upon by
journals in the twentieth century was vigorous peer review. Adherence to proven scientific methods, insistence on rigorous scientific
design, close attention to statistical analyses, and demanding that
interpretation not wander too far away from data are the hallmarks of sound peer review. Yet in the increasingly busy world of
science, there is less and less time for peer review. What can be done
to encourage this dimension of managing conflict of interest?
First, authors must understand that their papers will be subject
to vigorous peer review, including the possibility that raw data will
have to be provided to a reviewer. All authors should agree that if
asked, they will make this data promptly available.
Second, editors should not only thank peer reviewers but should
give consideration to publishing their reviews online after a sufficient period of time has lapsed after the publication or rejection
of a paper. Currently, peer review is blind, but that is not completely a good thing. Confidential reviewing may give reviewers the
cover to say what they wish, but blind review is still impossible for
outsiders to see and understand. Anonymity need not be extended
in perpetuity. Thought needs to be given to making reviews available in some form so that potential authors know what reviewers
expect, reviewers can learn from one another, those new to reviewing can see what is expected, and those who do a poor job can be
held accountable. Editors do some of these things, but readers and
other reviewers should be allowed a role in the process as well.
Peer reviewing should also become part of the process of gaining
promotion — not just an aspect of service but an expected and honored part of what it means to enter into the community of biomedicine and science. If you cannot do a competent peer review of a paper
in your field, then should you really be moving ahead in that field?
Senior leaders in the field must do their duty and show younger
members that peer review is not meant simply for the young.
Editors may also need to spend a bit more of their admittedly
meager budgets to try and retain more professional expertise in
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technical areas of review. Some journals now do this, and it makes
sense. Math and statistics are not for rank amateurs, but they
sometimes are handled by nonexperts even at the highest level of
peer review in major biomedical journals.
Last, the editors may want to supplement print publication
with an occasional online illustration of the discussion that takes
place around the acceptance or rejection of a particular paper.
Some anonymity is in order, but the door to the star-chamber of
editorial board decision making could be opened slightly to let
the masses see what goes on in weighing reviews, editorial judgment, and the desire to get the latest hot paper or author. Peer
review is best when, in the phrase used to describe the attitude
held by Henry Oldenburg, one of its first proponents, and the first
editor of the Royal Society of London’s Philosophical transactions,
it permits “. . . knocking men’s heads together to make the intellectual sparks fly . . . that the truth might emerge from the conflict of rival views” (8).
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The more heads let into the process of peer review, the more the
process is valued. The more the heads are trained to undertake the
process, the more the truth will emerge.
This is asking a lot. But conflict of interest is a tough problem. The editors of the JCI have shown themselves willing not
to shy away in the face of the most miserable aspect of the problem: money. Transparency and disclosure are the weapons they
have aggressively deployed. Peer review is the other great protection against conflicts of interest. It has weakened over the years.
The editors, readers, contributors, and reviewers for this journal
should give some consideration to whether my suggestions or others could help strengthen it.
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